|

A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer

RECRUITINGPhase 3Sponsored by Celltrion
Actively Recruiting
PhasePhase 3
SponsorCelltrion
Started2025-01-30
Est. completion2027-02
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06939595

Summary

The goal of this Phase 3 clinical trial is to compare efficacy and safety of CT-P51 and European Union (EU) approved Keytruda in combination with platinum pemetrexed chemotherapy in patients with previously untreated metastatic nsNSCLC.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Stage IV, non squamous NSCLC
* Have not received any prior systemic anti-cancer therapy for metastatic NSCLC
* Have at least 1 measurable lesion per RECIST version 1.1

Exclusion Criteria:

* Have predominantly squamous cell histology NSCLC.
* Hypersensitivity or contraindication to any component of the study drug, pemetrexed and cisplatin or carboplatin

Conditions3

CancerLung CancerNon-Squamous Non-Small Cell Lung Cancer

Browse More Trials

Cancer trialsLung Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.